NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

igc-ad1 igc pharma
IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →
igc-ad1
IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
Read More →
clincloud
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s
Read More →
artificial intelligence igc pharma
IGC Filed a Patent for a New Formulation to Treat Pain
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Receives a Notice of Allowance from the U.S. Patent Office
Read More →
igc pharma
IGC Reports Financial Results for Fiscal Year Ended March 31 2020
Read More →
igc pharma
Update to Notice to Investors
Read More →
igc pharma
IGC Announces Proposed Settlement of 3 Derivative Lawsuits & Provides Notice to Shareholders
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended December 31st, 2019
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended September 30, 2019
Read More →
igc-ad1 igc pharma
IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 Study
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended June 30, 2019
Read More →
artificial intelligence igc pharma
IGC to Participate in Arizona’s Industrial Hemp Program
Read More →
igc pharma
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2019
Read More →
igc pharma
IGC Provides Corporate Updates
Read More →